Bard/Endologix
This article was originally published in The Gray Sheet
Executive Summary
Bard passes on its option to acquire minimally invasive abdominal aortic aneurysm device maker Endologix but will remain exclusive distributor for the AAA product in Europe and Australia, the firm announces Dec. 14. The Endologix AAA device "continues to show promise;" however, "we do not believe this opportunity warrants the significant investment required" under the August 1999 option agreement, Bard explains. A fourth quarter charge will be taken in connection with the decision
You may also be interested in...
Radiance/Endologix Merger Combines AAA, Brachytherapy Pipelines
Endologix will gain R&D funding for its PowerLink abdominal aortic aneurysm system through a combination with brachytherapy device developer Radiance Medical Systems. A definitive merger pact was announced Feb. 11
Radiance/Endologix Merger Combines AAA, Brachytherapy Pipelines
Endologix will gain R&D funding for its PowerLink abdominal aortic aneurysm system through a combination with brachytherapy device developer Radiance Medical Systems. A definitive merger pact was announced Feb. 11
Bard R&D To Triple In Three Years Through Savings From Plant Consolidation
Consolidation of C.R. Bard manufacturing and non-manufacturing facilities over the next three years is expected to save the firm up to $70 mil. annually and allow the firm to roughly triple its R&D budget to about $150 mil. by 2004.